Reduction of fibroproliferative changes in irradiated XXXX lung with soluble transforming growth factor-b receptor.

@entity1 @entity8602 @entity575 @entity3794 @entity1810 @entity35
UNASSIGNED: The present study investigated whether established fibroproliferative changes in the irradiated @entity35 lung are histopathologically reduced by an adenovirus  -mediated soluble transforming growth factor (TGF)  - @entity8602 receptor. Replication  -defective adenoviral vectors expressing a type  II @entity1 @entity1810 receptor (AdTb  -ExR) were prepared. Male Fisher  -344 @entity35 were divided into the C, R and R  +  T groups. The @entity35 in the C group did not receive irradiation or treatment. The @entity35 in the R and R  +  T group each received 30  Gy irradiation to the right lung. Eight weeks following irradiation, the @entity35 in the R and R  +  T group were treated with saline or AdTb  -ExR, respectively. To analyze the @entity1810 expression, myofibroblast proliferation and macrophage/monocyte infiltration, sections of the lung were immunohistochemically stained at 16 weeks following irradiation. @entity575 staining was performed for semi  -quantitative evaluation of the fibroproliferative changes. Definitive @entity1810 expression, myofibroblast proliferation and macrophage/monocyte infiltration were observed in the lungs of the R group, but were significantly lower in the lungs of the R  +  T group. With respect to the fibroproliferative changes, the proportion of red  -stained areas in the R  +  T group was markedly lower than that in the R group. These data indicate that fibroproliferative changes induced by radiation are reversible and that @entity1810 has a critical role in fibroproliferative changes in the irradiated lung. The present results suggest that gene therapy with an adenoviral vector expressing a soluble @entity1810 receptor may be effective in reducing the established @entity3794 caused by radiation.
